申请人:The Du Pont Merck Pharmaceutical Company
公开号:US05416089A1
公开(公告)日:1995-05-16
Anticancer compounds of formula I: ##STR1## and pharmaceutically acceptable salts thereof, wherein: R.sup.1, R.sup.2 and R.sup.3 are independently selected H, CH.sub.3, NH.sub.2, NO.sub.2, and CN; R.sup.9 and R.sup.10 are H or alkyl or halo, X.sup.1 and Y.sup.1 or X.sup.2 and Y.sup.2, when present, join together to form, independently, a six membered 1N heterocycle substituted with 1-2 R.sup.3 ; or the group: ##STR2## wherein one of W or Z is C.dbd.O and the other is C.dbd.O, NH, S or O; or when X.sup.2 and Y.sup.2 are not joined together and when R.sup.2 is in the 4-position, then X.sup.2 and R.sup.2 may join together to form an ethylene bridge; are disclosed.
公式I的抗癌化合物:##STR1##及其药学上可接受的盐,其中:R.sup.1、R.sup.2和R.sup.3独立选择H、CH.sub.3、NH.sub.2、NO.sub.2和CN;R.sup.9和R.sup.10为H或烷基或卤素,当存在X.sup.1和Y.sup.1或X.sup.2和Y.sup.2时,它们独立地结合在一起形成一个六元1N杂环,被1-2个R.sup.3取代;或者该基团:##STR2## 其中W或Z之一为C.dbd.O,另一个为C.dbd.O、NH、S或O;或者当X.sup.2和Y.sup.2没有结合在一起且R.sup.2在4位时,那么X.sup.2和R.sup.2可以结合在一起形成一个乙烯桥。